Last updated: 02/20/2026 16:00:09
Study of GSK3359609 and pembrolizumab in programmed death receptor 1-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinomaINDUCE-3
EudraCT ID
EU CT Number
Not applicable
Trial status
Other
Other
Trial overview
Official title: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Trial description: The purpose of study is to evaluate if the addition of GSK3359609 to pembrolizumab as first-line treatment improves the efficacy of pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma/cancer (HNSCC).This is a randomized, double-blind, adaptive Phase II/III study comparing a combination of GSK3359609 inducible T cell co-stimulatory receptor (ICOS) agonist and pembrolizumab to pembrolizumab plus placebo in participants with programmed death receptor 1-ligand 1 (PD-L1) combined positive score (CPS) >=1 R/M HNSCC.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Overall survival (OS) in the programmed death receptor-ligand 1 (PD-L1) combined positive score (CPS) ≥1 population
Timeframe: Up to approximately 16 months
OS in the PD-L1 expression high (CPS ≥20) population
Timeframe: Up to approximately 16 months
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
Secondary outcomes:
PFS per immune-based RECIST (iRECIST) in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
PFS per RECIST in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
PFS per iRECIST (iPFS) in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
Milestone OS rate at 12 months in the PD-L1 CPS ≥1 population
Timeframe: 12 months
Milestone OS rate at 24 months in the PD-L1 CPS ≥1 population
Timeframe: 24 months
Milestone OS rate at 12 months in the PD-L1 CPS ≥20 population
Timeframe: 12 months
Milestone OS rate at 24 months in the PD-L1 CPS ≥20 population
Timeframe: 24 months
Overall Response Rate (ORR) per RECIST v1.1 in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
ORR per RECIST v1.1 in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
Disease Control Rate (DCR) per RECIST v1.1 in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
DCR per RECIST v1.1 in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
Duration of response (DoR) per RECIST v1.1 in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
DoR per RECIST v1.1 in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
Number of participants with any adverse events (AEs) and serious adverse events (SAEs)
Timeframe: Up to approximately 16 months
Number of participants with AEs by severity
Timeframe: Up to approximately 16 months
Number of participants with SAEs by severity
Timeframe: Up to approximately 16 months
Number of participants with adverse events of special interest (AESI)
Timeframe: Up to approximately 16 months
Number of participants with AESI by severity
Timeframe: Up to approximately 16 months
Number of participants with dose modifications
Timeframe: Up to approximately 16 months
Time to deterioration (TTD) in pain in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
TTD in pain in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
TTD in physical function in the PD-L1 CPS ≥1 population
Timeframe: Up to approximately 16 months
TTD in physical function in the PD-L1 CPS ≥20 population
Timeframe: Up to approximately 16 months
Interventions:
Enrollment:
320
Primary completion date:
2021-27-04
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Ballas M, Chisamore M, Cohen E, Daste A, Ellis C, Ferris R, et al. . INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2025; doi:10.1158/1078-0432.CCR-25-1197 https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-1197/771183/INDUCE-3-A-randomized-Phase-II-III-study-of-first?searchresult=1
PMID: 41427951
DOI: 10.1158/1078-0432.CCR-25-1197
Medical condition
Neoplasms, Head and Neck
Product
GSK3359609
Collaborators
Merck Sharp & Dohme Corp.
Study date(s)
November 2019 to June 2023
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Capable of giving signed informed consent
- Male or female, age >=18 years
- Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
- Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter
Inclusion and exclusion criteria
Inclusion criteria:
- Capable of giving signed informed consent
- Male or female, age >=18 years
- Histological or cytological documentation of Head and Neck Squamous Cell Carcinoma (HNSCC) that is considered incurable by local therapies
- Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx
- No prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of multimodal treatment for locally advanced disease)
- Measurable disease per RECIST version 1.1 guidelines
- ECOG Performance PS score of 0 or 1
- Adequate organ function
- Life expectancy of at least 12 weeks
- Female participants: must not be pregnant, not breastfeeding, and at least one of the following conditions apply: 1. Not a woman of childbearing potential (WOCBP) 2. A WOCBP who agrees to use a method of birth control from 30 days prior to randomization and for at least 120 days after the last dose of study treatment
- Male participants with female partners of child-bearing potential: must agree to use a highly effective contraception while receiving study treatment and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period
- Provide tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) acquired within 2 years prior to randomization for PD-L1 immunohistochemistry (IHC) testing by central laboratory
- Have PD-L1 Immunohistochemistry (IHC) CPS 1 status by central laboratory testing
- Have results from testing of Human Papilloma Virus (HPV) status for oropharyngeal cancer
Exclusion criteria:
- Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
- Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter
- Major surgery 28 days prior to randomization
- Has high risk of bleeding
- Toxicity related to prior treatment that has not resolved to <=Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be<= Grade 2)
- Received transfusion of blood products or administration of colony stimulating factors within 14 days prior to randomization
- Central nervous system (CNS) metastases, with the following exception: Participants with asymptomatic CNS metastases who are clinically stable and have no requirement for steroids for at least 14 days prior to randomization
- Invasive malignancy or history of invasive malignancy other than disease under study within the last 3 years, except as noted below: a. Any other invasive malignancy for which the participant was definitively treated, has been disease-free for 3 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical study
- Autoimmune disease or syndrome that required systemic treatment within the past 2 years
- Has a diagnosis of immunodeficiency or is receiving systemic steroids (≥10 mg oral prednisone per day or equivalent) or other immunosuppressive agents within 7 days prior to randomization
- Receipt of any live vaccine within 30 days prior randomization
- Prior allogeneic/autologous bone marrow or solid organ transplantation
- Has current pneumonitis or history of non-infectious pneumonitis that required steroids or other immunosuppressive agents
- Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions
- Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess
- Recent history of allergen desensitization therapy within 4 weeks of randomization
- History or evidence of cardiac abnormalities within the 6 months prior to randomization
- Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice
- Active infection requiring systemic therapy
- Known HIV infection, or positive test for hepatitis B active infection (presence of hepatitis B surface antigen), or hepatitis C active infection
- History of severe hypersensitivity to monoclonal antibodies or any ingredient used in the study treatment formulations
- Known history of active tuberculosis
- Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining informed consent, or compliance to the study procedures in the opinion of the investigator
- Is currently participating in (unless in follow-up phase and 4 weeks have elapsed from last dose of prior investigational agent), or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to date of randomization
- Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study
Trial location(s)
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Other
Actual primary completion date
2021-27-04
Actual study completion date
2023-20-06
Plain language summaries
Summary of results in plain language
Available language(s): English, Chinese (China), Chinese (Taiwan), Danish, Dutch, French (Canadian), French, German, German (Switzerland), Greek, Italian, Korean, Norwegian, Polish, Portuguese (Brazil), Portuguese (Native), Romanian, Russian (Israel), Russian, Spanish (Argentina), Spanish (Mexico), Spanish, Japanese, Arabic (Israel), Hebrew
To view plain language summaries on trialsummaries.com click here.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website